The latest analysis from The North American COVID-19 STEMI (NACMI) was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions.
May 19, 2022
International COVID-19 Registry Finds Significant Increased Risk of In-hospital Mortality for STEMI Patients with COVID-19 Compared to Pre-pandemic
May 19, 2022 — The latest analysis from The North American COVID-19 STEMI (NACMI) was presented today as late-breaking…
Read More
30-day findings from the DIPRA study demonstrate distal radial artery access poses no increased hand dysfunction risk
May 19, 2022
Novel Distal Radial Access for Cardiac Catheterization Shown as a Safe Strategy Compared to Conventional Radial Access
May 19, 2022 — Initial findings from the Distal versus Proximal Radial Artery Access for Cardiac Catheterization and…
Read More
Study evaluates therapy optimization and system management of endovascular pulmonary neuromodulation in ADHF
May 19, 2022
Cardionomic Announces First Patient Enrolled in STIM-ADHF Study
May 19, 2022 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial enrollment in…
Read More
Results show potential to monitor ECG data in a non-clinical setting
May 18, 2022
New App for Apple Watch Uses Artificial Intelligence to Detect Left-ventricular Dysfunction
May 18, 2022 — A new app developed by the Mayo Clinic transmits Apple Watch electrocardiograms (ECG) signals recorded…
Read More
Hands-free robotic insertion and steering of ablation probes using XACT ACE Robotic System offers health systems the potential to improve accuracy, consistency, and efficiency of procedures
May 18, 2022
XACT Robotics Receives FDA Clearance that Expands Support for Ablation Procedures
May 18, 2022 — XACT Robotics, developer of the world’s first and only comprehensive robotic system for interventional…
Read More
Preliminary findings include a 15% relative CVD risk reduction within eight weeks
May 18, 2022
Time-restricted Eating May Lower CVD Risk for Older Breast Cancer Survivors
May 18 2022 — Older breast cancer survivors with cardiometabolic risk factors who restricted food intake to eight hours…
Read More
Findings help identify patients who may not be optimally managed for recurrent stroke prevention
May 18, 2022
Continuous Monitoring Detects Four Times More Atrial Fibrillation Incidence Following Stroke than Intermittent Monitoring
May 18, 2022 — Continuous monitoring with an insertable cardiac monitor (ICM) is shown to be more successful in…
Read More
Khaldoon Alaswad, M.D., director of catheterization lab at Henry Ford Hospital in Detroit. Image courtesy of Henry Ford Health
May 18, 2022
Henry Ford Cardiologist to Perform a Live Heart Procedure at International Medical Education Event
May 18, 2022 — For the third straight year, Henry Ford Hospital interventional cardiologist Khaldoon Alaswad, M.D. will…
Read More
Results indicate Black patients are 25% less likely to receive stroke-preventing medication
May 17, 2022
Study of National Registry Uncovers Racial Disparities Around Anticoagulation for Atrial Fibrillation
May 17, 2022 — Results of a new study reveal Black patients hospitalized with atrial fibrillation (AF) are under-…
Read More
Innovative care strategy created in response to COVID-19 pandemic emphasizes the role telemedicine plays in post-op patient monitoring
May 17, 2022
New Study Shows Benefits of Same Day Discharge for Atrial Fibrillation Ablation Patients
May 17, 2022 — Results from a new study show success of intended same day discharge (SDD) improves over time for…
Read More
Heart Rhythm 2022 has come to a close, and the Heart Rhythm Society has released some stats regarding this year's conference. More than 7,700+ heart rhythm professionals from around the world whose participation during Heart Rhythm 2022
May 17, 2022
Heart Rhythm 2022 Highlights
May 17, 2022 — Heart Rhythm 2022 has come to a close, and the Heart Rhythm Society has released some stats regarding…
Read More
Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs
May 17, 2022
Research Shows Potential to Reduce Major Cardiovascular (CV) Events
May 17, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost-…
Read More
On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the American College of Cardiology (JACC), egnite, Inc. announced that it has expanded the company’s focus beyond structural heart disease into cardiovascular (CV) disease, starting with atrial fibrillation (AF).
May 17, 2022
egnite, Inc. Expands into Cardiovascular Disease Supported by New Data on the State of Care for Patients with Atrial Fibrillation
May 17, 2022 — On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of…
Read More
Seamless integration and communication between Philips Ultrasound System - EPIQ CVxi - and Philips Image Guided Therapy System - Azurion - supports efficient fusion-imaging workflow for minimally-invasive treatment of structural heart disease
May 16, 2022
Philips EchoNavigator Helps Interventional Teams Treat Structural Heart Disease
May 16, 2022 — Philips, a global leader in health technology, announced at EuroPCR (17 - 20 May 2022, Paris, France)…
Read More
Boston Scientific announced that Peter M. “Pete” Nicholas, co-founder and former CEO of Boston Scientific from 1979 to 1999 and a corporate visionary in the minimally invasive surgery industry, passed away peacefully on May 14 just a few days before his 81st birthday. 
May 16, 2022
Boston Scientific Co-founder and Former CEO Passes Away
May 16, 2022 — Boston Scientific announced that Peter M. “Pete” Nicholas, co-founder and former CEO of Boston…
Read More
Key members of the research collaboration: (from left) Prof Roger Foo (Programme Director, ATTRaCT, and Senior Group Leader, GIS), Dr Karin Conde-Knape (Senior Vice President, Global Drug Discovery, Novo Nordisk), Dr Rasmus Rabøl (Corporate Vice President, Global Translation, Novo Nordisk), Dr Natasha Michaelsen (Principal Scientist, Global Translation, Novo Nordisk), Prof Mark Richards (Director, Cardiovascular Research Institute, NUS, and Deputy Director, National University Heart Centre), Prof Derek Haus
May 16, 2022
A*STAR, NHCS, NUS, and Novo Nordisk to Collaborate on Cardiovascular Disease Research
May 16, 2022 — The Agency for Science, Technology and Research’s (A*STAR) Genome Institute of Singapore (GIS) and…
Read More
A substantial proportion of patients with COVID and shock had low CI despite preserved EF, suggesting underfilling of the LV, but this proportion was smaller in W2. This difference could not be explained by changes in PEEP between cohorts. This suggests that fluid management strategies may have been more aggressive in W2.
May 16, 2022
New Report Published Comparing Hemodynamics of Cardiac Shock in COVID-19 Patients in Pandemic’s First Vs. Second Wave
May 16, 2022 — A new report by a team of cardiologists from the Heart & Vascular Hospital, Hackensack Meridian…
Read More
Pump housing and impeller design. (A): (left) Axial flow pump: HeartMate II LVAD (taken from Figure 2 in the HeartMate II left ventricular assist system instructions for use). (B) (right) Centrifugal flow pump: HeartWare assist device (taken from Figure 2 in the HeartWare assist device patient manual).
May 16, 2022
Study Finds that Concurrent Tricuspid Valve Surgery and Left Ventricular Assist Device Implantation do not Appear to Lower the Incidence of Right Heart Failure
May 16, 2022 — Right heart failure (RHF) continues to be a major source of morbidity and mortality following left…
Read More
CRF Meeting Covering Structural Heart Disease Innovations Will Take Place June 8-10
May 16, 2022
Late-Breaking Science Announced for TVT 2022
May 16, 2022 — The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will…
Read More
Mavacamten estimated sales just shy of $1 billion if approved for common cardiomyopathy subtype, says GlobalData
May 13, 2022
Bristol Myers Squibb’s Mavacamten Poised to Stand unchallenged
May 13, 2022 — Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now